NCT04671251View on ClinicalTrials.gov

Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

December 15, 2020

Primary Completion Date

March 30, 2022

Study Completion Date

March 30, 2022

Conditions
Multiple Myeloma
Interventions
DRUG

AEVI-007

50 mg of AEVI-007 and will be reconstituted with 1.2 mL of water for injection.

Trial Locations (7)

20817

American Oncology Partners of Maryland, PA, Bethesda

28204

Levine Cancer Institute, Charlotte

32746

Florida Cancer Specialists, Lake Mary

34232

Florida Cancer Specialists, Sarasota

53226

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee

90069

James R. Berenson, MD., Inc., West Hollywood

95817

University of California, Davis Comprehensive Cancer Center, Sacramento

Sponsors
All Listed Sponsors
lead

Avalo Therapeutics, Inc.

INDUSTRY

NCT04671251 - Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter